{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:10:44Z","timestamp":1770448244621,"version":"3.49.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Dapagliflozin (trade name FARXIGA) is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has transcended its initial antidiabetic application to demonstrate benefits in cardiac and renal diseases. It was first approved by the food and department administration for type 2 diabetes in 2014. Since then, it has gained food and department administration approval for chronic kidney disease in 2021, heart failure with reduced ejection fraction in 2020, and heart failure with preserved ejection fraction in 2023. Thus, dapagliflozin plays a pivotal role in improving patient outcomes. By competitive binding to renal SGLT-2 cotransporters, dapagliflozin effectively prevents glucose and sodium reabsorption, leading to glucosuria. Its pharmacokinetic profile involves minimal cytochrome P450-induced metabolism, rapid absorption with an 18-hour duration of action, and stable effects. Clinical trials have revealed dapagliflozin\u2019s efficacy in glycemic control without the risk of hypoglycemia, making it an advantageous choice for patients insufficiently managed on other antidiabetic drugs. Comparative analysis with other SGLT-2 inhibitors suggests dapagliflozin\u2019s potential superiority in preventing heart failure. Compared to empagliflozin, it has more extended effects, contributing to stable sodium diuresis, reduced blood pressure fluctuations, and potentially lower cardiovascular disease risks. However, it leads to less urinary glucose excretion compared with canagliflozin. Dapagliflozin has specific contraindications, such as type 1 diabetes and end-stage chronic kidney disease. Adverse effects include an increased risk of genital infections, urinary tract infections, and Fournier\u2019s gangrene. A nuanced understanding of dapagliflozin\u2019s benefits and limitations is imperative for informed clinical decision-making in the management of diabetes and its complications.<\/jats:p>","DOI":"10.1097\/crd.0000000000000694","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:07:49Z","timestamp":1714122469000},"page":"186-191","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["SGLT-2 Inhibitors: Focus on Dapagliflozin"],"prefix":"10.1097","volume":"34","author":[{"given":"Zoya","family":"Siddiqui","sequence":"first","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somar","family":"Hadid","sequence":"additional","affiliation":[{"name":"School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"R1-20260206","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/endocrines4030045","article-title":"Exploring SGLT-2 inhibitors: benefits beyond the glucose-lowering effect\u2014what is new in 2023?","volume":"4","author":"Young","year":"2023","journal-title":"Endocrines"},{"key":"R2-20260206","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","article-title":"Dapagliflozin: a review in type 2 diabetes.","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"R3-20260206","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1871525714666151106121215","article-title":"A review of sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin and empagliflozin.","volume":"13","author":"Syed","year":"2015","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"R4-20260206","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus.","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"R5-20260206","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2215\/CJN.10180916","article-title":"Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function.","volume":"12","author":"Petrykiv","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-20260206","doi-asserted-by":"crossref","first-page":"6798","DOI":"10.3390\/jcm12216798","article-title":"Current role of SLGT2 inhibitors in the management of the whole spectrum of heart failure: focus on dapagliflozin.","volume":"12","author":"Escobar","year":"2023","journal-title":"J Clin Med"},{"key":"R9-20260206","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease.","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"key":"R10-20260206","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose Co-Transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology.","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"R11-20260206","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2337\/db17-0100","article-title":"Empagliflozin and kinetics of renal glucose transport in healthy individuals and individuals with type 2 diabetes.","volume":"66","author":"Al-Jobori","year":"2017","journal-title":"Diabetes"},{"key":"R12-20260206","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"R13-20260206","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12933-023-02027-8","article-title":"Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.","volume":"22","author":"Koshino","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"R14-20260206","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jchf.2021.05.006","article-title":"Empagliflozin-induced changes in epicardial fat: the centerpiece for myocardial protection?","volume":"9","author":"Mullens","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R15-20260206","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction.","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R16-20260206","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study.","volume":"9","author":"Requena-Ibanez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R17-20260206","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/FJC.0000000000000007","article-title":"Cardiac titin and heart disease.","volume":"63","author":"LeWinter","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"R18-20260206","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of empagliflozin on hemodynamics in patients with heart failure and reduced ejection fraction.","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R21-20260206","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/dia.2018.0052","article-title":"Effects of dapagliflozin on 24-hour glycemic control in patients with type 2 diabetes: a randomized controlled trial.","volume":"20","author":"Henry","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"R22-20260206","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1310\/hpj4907-647","article-title":"Dapagliflozin.","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp Pharm"},{"key":"R23-20260206","first-page":"8S","article-title":"SGLT2 inhibitors for type 2 diabetes mellitus treatment.","volume":"32","author":"Plodkowski","year":"2015","journal-title":"Fed Pract"},{"key":"R24-20260206","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/2042018814558243","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus.","volume":"6","author":"Filippatos","year":"2015","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R25-20260206","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"R26-20260206","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"R27-20260206","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R28-20260206","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/2042018818771434","article-title":"Use of dapagliflozin as an add-on to insulin therapy in patients with suboptimally controlled type 2 diabetes.","volume":"9","author":"Das","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R29-20260206","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(22)00052-3","article-title":"Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study.","volume":"10","author":"Tamborlane","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R30-20260206","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients.","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"R31-20260206","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R32-20260206","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5334\/gh.1258","article-title":"Effect of dapagliflozin in patients with heart failure: a systematic review and meta-analysis.","volume":"18","author":"Ali","year":"2023","journal-title":"Glob Heart"},{"key":"R33-20260206","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R34-20260206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"R35-20260206","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2337\/dc20-2492","article-title":"Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58.","volume":"44","author":"Cahn","year":"2021","journal-title":"Diabetes Care"},{"key":"R36-20260206","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes.","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"R37-20260206","doi-asserted-by":"crossref","first-page":"e010080","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial.","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ Heart Fail"},{"key":"R38-20260206","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R39-20260206","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations.","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"R41-20260206","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"R43-20260206","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/IJNRD.S234282","article-title":"Clinical evaluation of dapagliflozin in the management of CKD: focus on patient selection and clinical perspectives.","volume":"15","author":"Nashar","year":"2022","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"R44-20260206","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4103\/ijem.IJEM_159_17","article-title":"Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus.","volume":"22","author":"Unnikrishnan","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"R45-20260206","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.9778\/cmajo.20180111","article-title":"Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials.","volume":"6","author":"Donnan","year":"2018","journal-title":"CMAJ Open"},{"key":"R46-20260206","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2147\/VHRM.S111991","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.","volume":"12","author":"Reed","year":"2016","journal-title":"Vasc Health Risk Manag"},{"key":"R47-20260206","doi-asserted-by":"crossref","first-page":"317507","DOI":"10.1155\/2015\/317507","article-title":"Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.","volume":"2015","author":"Zanoli","year":"2015","journal-title":"ScientificWorldJournal"},{"key":"R48-20260206","doi-asserted-by":"crossref","first-page":"3695101","DOI":"10.1155\/2020\/3695101","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the US FDA adverse event reporting system.","volume":"2020","author":"Hu","year":"2020","journal-title":"J Diabetes Res"},{"key":"R49-20260206","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1111\/dom.13281","article-title":"Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: impact on glycaemic control at a general practice level in England.","volume":"20","author":"Heald","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R50-20260206","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jphs.2016.02.003","article-title":"Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.","volume":"130","author":"Tahara","year":"2016","journal-title":"J Pharmacol Sci"},{"key":"R51-20260206","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12933-019-0919-9","article-title":"Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R52-20260206","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00392-021-01913-z","article-title":"Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis.","volume":"111","author":"T\u00e4ger","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"R53-20260206","first-page":"593","article-title":"Comparison Of efficacy and safety profile of empagliflozin versus dapagliflozin as add on therapy in type 2 diabetic patients.","volume":"33","author":"Hussain","year":"2021","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"R54-20260206","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R55-20260206","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s12325-020-01549-x","article-title":"Real-world comparative effectiveness of canagliflozin versus empagliflozin and dapagliflozin in patients with type 2 diabetes in the United States.","volume":"38","author":"Blonde","year":"2021","journal-title":"Adv Ther"},{"key":"R56-20260206","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/dom.12418","article-title":"Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.","volume":"17","author":"Sha","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R57-20260206","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"R58-20260206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.13492","article-title":"Cardiovascular protection in type 2 diabetes: insights from recent outcome trials.","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:01:13Z","timestamp":1770390073000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000694","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}